Perspectives in clinical gastroenterology and hepatologyStatins and Colorectal Cancer
Section snippets
Experimental Evidence: Anticancer Mechanisms of Statins
The interest in statins as modifiers of cancer risk spawned a large number of experimental studies examining the antineoplastic effects of statins in cellular and animal models of human cancer.10, 11 Inhibition of HMG-CoA reductase by statins leads not only to a decrease in cholesterol synthesis, but also to reduced generation of other intermediates of the mevalonate pathway, including the nonsterol isoprenoids, farnesyl pyrophosphate and geranylgeranyl pyrophosphate.5 Farnesyl pyrophosphate
Statins and Colorectal Cancer Risk in Randomized Trials
As a result of numerous large RCTs of lipid-lowering and major vascular events, a wealth of clinical data on statin use has accrued. Most statin RCTs have reported data on overall cancer incidence, and some studies have reported site-specific incidence (Table 1).17, 53, 54, 55, 56, 57, 58, 59, 60 Thus, cardiovascular RCTs represent a valuable resource for assessing differences in cancer incidence between groups in which statin use has been randomly assigned. Several tabular meta-analyses of RCT
Case-Control Studies
Case-control studies are generally able to efficiently examine associations between remote exposures and risk of disease, whereas cohort studies can be valuable in dissecting time-dependent associations between exposures and outcomes. A large number of observational studies have assessed the association between statin use and colorectal cancer (Table 2). Perhaps the most publicized and highly cited of these studies is the analysis by Poynter et al,26 based on the Molecular Epidemiology of
Statins and Risk of Colorectal Adenomas
Even short-term statin use may be sufficient to influence the evolution or progression of colorectal adenomas, the precursors to the vast majority of colorectal cancers (Table 3). In a retrospective analysis conducted in more than 2500 veterans with a history of colonoscopic polypectomy for adenomas, Siddiqui et al87 showed a 49% reduction in the incidence of recurrent adenomas, and a 29% reduction in the incidence of advanced adenomas, associated with continuous statin use over 3 to 5 years.
Statin Use After a Diagnosis of Colorectal Cancer
Another high-risk group, in whom it may be possible to show benefit from statin use in shorter-term studies, are individuals who have already developed colorectal cancer. In a retrospective cohort study of 1309 male veterans with colorectal cancer,92 more than 3 years of prediagnosis statin use was associated with lower tumor stage, lower prevalence of metastases, and higher frequency of proximal cancers, compared with nonusers. Survival analysis showed more favorable 5-year cancer-specific
Statins and Combination Chemoprevention
Even if statins, when used alone, are judged to be ineffective at reducing the risk of colorectal neoplasia, their use in combination with other agents, such as NSAIDs or aspirin, may still prove to be a successful chemopreventive strategy.98 Experimental evidence suggests that statins act synergistically with NSAIDs, and cyclooxygenase-2 inhibitors, to induce cell-cycle arrest and apoptosis in human colorectal cancer cell lines.40, 99 In an animal model, statins, in combination with NSAIDs or
Summary and Future Perspectives
An abundance of experimental data have provided a variety of biologically plausible mechanisms through which statins might affect the initiation or evolution of colorectal neoplasia. Evidence from clinical studies is, however, conflicting. Studies supporting a chemopreventive role for statins in colorectal neoplasia are relatively few in number and are almost exclusively of retrospective observational design. Although the magnitude of risk reduction observed in the case-control study by Poynter
Acknowledgment
The content is solely the responsibility of the authors.
References (101)
- et al.
Recent development in pleiotropic effects of statins on cardiovascular disease through regulation of transforming growth factor-beta superfamily
Cytokine Growth Factor Rev
(2011) Might treatment of hypercholesterolaemia increase non-cardiac mortality?
Lancet
(1991)- et al.
Statins and cancer: a systematic review and meta-analysis
Eur J Cancer
(2008) - et al.
Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity
J Biol Chem
(2004) - et al.
Involvement of oxidative stress in simvastatin-induced apoptosis of murine CT26 colon carcinoma cells
Toxicol Lett
(2010) - et al.
Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer
J Biol Chem
(2007) - et al.
The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway
Gastroenterology
(2007) - et al.
Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatinThe JUPITER trial (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)
J Am Coll Cardiol
(2011) - et al.
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial
Lancet
(2011) - et al.
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
Lancet
(2002)
Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study
Gastroenterology
Neither long-term statin use nor atherosclerotic disease is associated with risk of colorectal cancer
Clin Gastroenterol Hepatol
Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk
Ann Epidemiol
Reduction in low-density lipoprotein cholesterol levels during statin therapy is associated with a reduced incidence of advanced colon polyps
Am J Med Sci
Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
Eur J Biochem
HMG-CoA reductase inhibitors for treatment of hypercholesterolemia
N Engl J Med
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
Lancet
Health, United States, 2011: with special feature on socioeconomic status and health
Pharmacological actions of statins: a critical appraisal in the management of cancer
Pharmacol Rev
Statin effects beyond lipid lowering—are they clinically relevant?
Eur Heart J
Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials
Curr Pharm Des
Beneficial cardiovascular pleiotropic effects of statins
Circulation
Therapy insight: potential of statins for cancer chemoprevention and therapy
Nat Clin Pract Oncol
Statins and cancer prevention
Nat Rev Cancer
Serum cholesterol and cancer risk: an epidemiologic perspective
Annu Rev Nutr
Invited commentary: low blood cholesterol, nonillness mortality, and other nonatherosclerotic disease mortality: a search for causes and confounders
Am J Epidemiol
Time trends in serum cholesterol before cancer death
Epidemiology
Carcinogenicity of lipid-lowering drugs
JAMA
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levelsCholesterol and recurrent events trial investigators
N Engl J Med
Statin use and the risk of breast and prostate cancer
Epidemiology
Statins and cancer risk: a meta-analysis
JAMA
Statins and risk of cancer: a systematic review and metaanalysis
Int J Cancer
Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials
J Clin Oncol
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study
Arch Intern Med
The risk of cancer in users of statins
J Clin Oncol
Cancer risk among statin users: a population-based cohort study
Int J Cancer
Statins and the risk of colorectal cancer
N Engl J Med
Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study
Int J Cancer
The association between statins and cancer incidence in a veterans population
J Natl Cancer Inst
Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes
Am J Gastroenterol
RAS oncogenes: weaving a tumorigenic web
Nat Rev Cancer
Role of rho GTPases and their regulators in cancer progression
Front Biosci
Targeting tumor cell metabolism with statins
Oncogene
The antioxidant effects of statins
Coron Artery Dis
Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site
Nat Med
Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin
Int J Oncol
IL-6 and IL-8 responses of colorectal cancer in vivo and in vitro cancer cells subjected to simvastatin
J Physiol Pharmacol
Immunomodulator activity of 3-hydroxy-3-methylglutaryl-CoA inhibitors
Cardiovasc Hematol Agents Med Chem
Diverse effects of statins on angiogenesis: new therapeutic avenues
Pharmacotherapy
Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells
Clin Cancer Res
Cited by (71)
Regorafenib activates oxidative stress by inhibiting SELENOS and potentiates oxaliplatin-induced cell death in colon cancer cells
2023, European Journal of PharmacologyAGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia: Expert Review
2021, Clinical Gastroenterology and HepatologyCitation Excerpt :HMG-CoA reductase inhibitors, also known as statins, are widely used to treat hypercholesterolemia and cardiovascular disease. Statins have multiple antiproliferative properties and inhibit the biosynthesis of cholesterol, which appears to play a critical role in the progression of several types of cancer including CRC.75–77 Among individuals with CRC, the role of statins is inconclusive.
Primary prevention of CRC
2021, Foundations of Colorectal CancerChemoprevention of Colorectal Cancer
2020, GastroenterologyBig data approach in the field of gastric and colorectal cancer research
2024, Journal of Gastroenterology and Hepatology (Australia)
This article has an accompanying continuing medical education activity on page e13. Learning Objectives—At the end of this activity, the successful learner will be able to appraise the current evidence relating to statins in the prevention and treatment of colorectal neoplasia.
Conflicts of interest This author discloses the following: Andrew Chan has consulted for Bayer Healthcare, Millennium Pharmaceuticals, and Pfizer, Inc. The remaining author discloses no conflicts.
Funding Supported by a Clinical Academic Fellowship from the Chief Scientist Office of the Scottish Government (P.L.), and a Damon Runyon Clinical Investigator award (A.C.).